Mark Currie, Ph.D.
President , Cyclerion

Mark Currie joined our board of directors in April 2019. Dr. Currie brings world-leading R&D expertise across many disease areas including GI, having pioneered the discovery and development of LINZESS® (linaclotide) as well as the discovery and development of Ironwood’s leading GI development candidates, IW-3718 and MD-7246. He is president of Cyclerion Therapeutics, Inc. Prior to this role, he was most recently senior vice president, chief scientific officer and president of R&D at Ironwood. Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor Inc. He also initiated, built and led discovery pharmacology and served as director of arthritis and inflammation at Monsanto Company, leading an effort that resulted in marketed COX‐2 inhibitors for the treatment of pain in humans and animals. Dr. Currie earned a Ph.D. in cell biology from the Bowman Gray Center for Medical Education at Wake Forest University and a B.S. in biology from the University of South Alabama.

Copyright © 2019, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.